Cancer Treatment Reviews

Papers
(The TQCC of Cancer Treatment Reviews is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Claudins as diagnostic tools and therapeutic targets—Glimpse of the horizon242
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?145
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing140
Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer123
Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?119
First line treatment of BRAF mutated advanced melanoma: Does one size fit all?117
Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms114
Acknowledgement to Reviewers 2021112
Editorial Board93
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?90
Editorial Board87
Liquid biopsy after resection of pancreatic adenocarcinoma and its relation to oncological outcomes. Systematic review and meta-analysis78
Editorial Board75
Current state of play for HPV-positive oropharyngeal cancers71
Editorial Board67
Local control strategies for management of NSCLC with oligoprogressive disease66
Editorial Board63
CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer62
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review60
Editorial Board58
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers55
Editorial Board52
Managing postoperative biochemical relapse in prostate cancer, from the perspective of the Francophone group of Urological radiotherapy (GFRU)51
Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations50
Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy49
Mobile applications for early breast cancer chemotherapy-related symptoms reporting and management: A scoping review48
Comparative analysis of international guidelines on the management of advanced non-functioning well-differentiated pancreatic neuroendocrine tumors45
De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: A systematic review and meta-analysis44
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in44
The COVID-19 pandemic: An opportunity to rethink and harmonise the frequency of follow-up visits for patients with early stage breast cancer43
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)42
NTRK gene fusion testing and management in lung cancer41
Evolution of the HIF targeted therapy in clear cell renal cell carcinoma41
Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group40
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice40
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials39
Artificial intelligence for prediction of treatment outcomes in breast cancer: Systematic review of design, reporting standards, and bias39
Treatment landscape of metastatic pancreatic cancer39
Practical clinical management of ocular adverse events related to Antibody-Drug Conjugates in gynaecological malignancies39
Desmoplastic Small Round Cell Tumors: A review with focus on clinical management and therapeutic options37
The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: A systematic review37
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review36
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer36
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies35
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer35
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review35
Understanding the immuno-biology of oesophageal adenocarcinoma: Towards improved therapeutic approaches34
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes33
Adenocarcinoma spectrum lesions of the lung: Detection, pathology and treatment strategies33
The role of transforming growth factor β in upper gastrointestinal cancers: A systematic review31
Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review31
Advances and challenges in immunotherapy for locally advanced nasopharyngeal carcinoma30
177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers30
Proton beam therapy for children and adolescents and young adults (AYAs): JASTRO and JSPHO Guidelines30
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives30
Neurological complications of cancer immunotherapy30
Precision medicine for multiple myeloma: The case for translocation (11;14)30
Current advances in targeted therapy for metastatic colorectal cancer – Clinical translation and future directions30
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications29
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis29
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer29
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges28
Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants28
Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon28
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer28
Systemic therapy for older patients with early breast cancer27
Microsatellite instability in Gastric Cancer: Between lights and shadows27
Systematic review of fetal and placental metastases among pregnant patients with cancer27
The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer27
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification27
Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes27
Cabozantinib: An evolving therapy for hepatocellular carcinoma27
Radiomics and radiogenomics in head and neck squamous cell carcinoma: Potential contribution to patient management and challenges27
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas26
Beyond HER2: Targeting the ErbB receptor family in breast cancer25
Editorial Board25
GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee25
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis25
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer25
Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review24
PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives24
The gut wall’s potential as a partner for precision oncology in immune checkpoint treatment23
Oncological outcomes of multimodality treatment for patients undergoing surgery for locally recurrent rectal cancer: A systematic review23
Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS –GROUP). Part II23
Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS – GROUP). Part I22
Antibody based therapies in Hodgkin lymphoma22
Oncological risks associated with the planned watch-and-wait strategy using total neoadjuvant treatment for rectal cancer: A narrative review21
Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis21
Impact of molecular profiling on the management of patients with myelofibrosis21
Hormone receptor-positive early breast cancer in young women: A comprehensive review21
Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives21
Locally advanced and metastatic endometrial cancer: Current and emerging therapies21
Patient-reported outcome measure to implement routine assessment of cancer survivors’ unmet needs: An overview of reviews and COSMIN analysis21
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project20
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives20
Review: Targeting EZH2 in neuroblastoma20
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?20
Proton pump inhibitors and cancer treatments: Emerging evidence against coadministration20
The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review19
Strategies for improving detection of circulating tumor DNA using next generation sequencing19
Molecular aspects of brain metastases in breast cancer19
Outcomes and toxicities of re-irradiation for prostate cancer: A systematic review on behalf of the Re-Irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)19
If it’s a target, it’s a pan-cancer target: Tissue is not the issue19
Editorial Board19
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis18
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis18
Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives18
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer18
Editorial Board17
Pharmacotherapy for leptomeningeal disease in breast cancer17
Breast reconstruction and radiation therapy: An Italian expert Delphi consensus statements and critical review17
Optimizing lung cancer radiation therapy: A systematic review of multifactorial risk assessment for radiation-induced lung toxicity17
Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news17
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?17
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches17
Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies17
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis17
Editorial Board16
Editorial Board16
Regulatory T cells in gastric cancer: Key controllers from pathogenesis to therapy16
Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors16
Editorial Board16
High-dose administration of tyrosine kinase inhibitors to improve clinical benefit: A systematic review16
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features16
nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives16
Editorial Board16
Compliance to chemoradiation in squamous cell carcinoma of the anus16
Engineering strategies to optimise adoptive cell therapy in ovarian cancer16
0.07426905632019